Mechanism of Action
50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC 50 values of 3.2 and 5.0 nM, respectively, and other kinases, such as SIK1, NEK11, and LIMK1 at higher concentrations. Some…
Indications (3)
Clinical Trials (5)
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7994185 | Jan 20, 2030 | SubstanceProduct | — |
| 8415345 | Jan 20, 2030 | SubstanceProduct | — |
| 8415345*PED | Jul 20, 2030 | — | |
| 7994185*PED | Jul 20, 2030 | — | |
| 8703781 | Oct 15, 2030 | SubstanceProduct | U-3565 |